CATALENT, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.81 USD | -0.30% |
|
-1.22% | +24.22% |
| May. 09 | MOVES -Lazard hires veteran healthcare dealmaker Colocci as vice chairman | RE |
| May. 08 | Earnings Flash (CTLT) CATALENT Posts Q3 Revenue $1.07B | MT |
ETFs positioned on Catalent, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 1,006 M€ | -.--% | ||
| 0.01% | 414 M€ | +11.90% | - | |
| 0.00% | 0 M€ | +0.34% | - | |
| 0.00% | 0 M€ | +0.32% | - | |
| 0.00% | 2 M€ | +3.16% | - | |
| 0.00% | 0 M€ | +3.95% | - | |
| 0.00% | 0 M€ | +3.63% | - | |
| 1.32% | 0 M€ | +6.50% | - |
Catalent, Inc. is specialized in pharmaceutical outsourcing services. The group offers solutions for the development and formulation of drugs, biological products and animal health products. Net sales break down by activity as follows:
- provision of development services and clinical supply services (55.4%);
- subcontracted manufacturing services (44.6%).
Net sales are distributed geographically as follows: the United States (63.2%), Europe (28.7%) and other (8.1%).
Sector
Pharmaceuticals
Calendar
2024-05-28
- Extraordinary Shareholders Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
55.81
USD
Average target price
63.5
USD
Spread / Average Target
+13.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.22% | 10.1B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- CTLT Stock
- Funds and ETFs Catalent, Inc.
